RNS Number : 9171Z Renalytix PLC 17 January 2024 Renalytix plc ("Renalytix" or the "Company") Update on kidneyIntelX.dkd Local Coverage Determination Consideration Local Coverage Determination would result in contracted coverage for an estimated additional five million Medicare patients
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months Results demonstrated a 61% increase in preventative drug prescriptions among patients in the high-risk
RNS Number : 1665Z Renalytix PLC 10 January 2024 Renalytix plc ("Renalytix" or the "Company") New published data for KidneyIntelX™ New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease Electronic health record deployment of
RNS Number : 0685X Renalytix PLC 18 December 2023 Renalytix plc ("Renalytix" or the "Company") Issue of Shares LONDON and SALT LAKE CITY - December 18, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the Company's convertible bond and the
RNS Number : 0572X Renalytix PLC 15 December 2023 Renalytix plc (" Renalytix " or the " Company ") Result of AGM LONDON and SALT LAKE , 15 December 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical
RNS Number : 2472W Renalytix PLC 08 December 2023 Renalytix plc ("Renalytix" or the "Company") Directorate Change LONDON and SALT LAKE CITY - December 8, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on
RNS Number : 3917U Renalytix PLC 23 November 2023 Renalytix plc ("Renalytix" or the "Company") Grant of Share Options LONDON and SALT LAKE CITY - November 23, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on
RNS Number : 8806T Renalytix PLC 17 November 2023 Renalytix plc ("Renalytix" or the "Company") Publication of Annual Report 2023 and Notice of 2023 Annual General Meeting LONDON and SALT LAKE CITY, UT November, 17 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Annual
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today
RNS Number : 3099T Renalytix PLC 14 November 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024 LONDON and SALT LAKE CITY , November 14, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial